Madrigal Pharmaceuticals, Inc., formerly Synta Pharmaceuticals Corp., incorporated on March 10, 2000, is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and nonalcoholic steatohepatitis (NASH). The Company's lead product, MGL-3196, is a Phase II-ready once-daily, oral, liver-directed selective thyroid hormone receptor-b (THR-b) agonist for the treatment of NASH, and heterozygous and homozygous familial hypercholesterolemia (FH). Its product pipeline also includes MGL-3745, which is used in the treatment of NASH and FH. MGL-3196 has completed Phase I single and multiple dose trials in healthy volunteers. MGL-3196 is being developed for dyslipidemia/hypercholesterolemia to lower low-density lipoproteins (LDL) cholesterol, triglyceride levels and lipoprotein(a).
MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action. MGL-3196 specifically targets receptors in the liver involved in metabolism and cholesterol regulation, and avoids side effects associated with thyroid hormone receptor activation outside the liver, including those mediated by THR-a receptors. MGL-3196 is a regulator of hepatic triglyceride metabolism and cholesterol metabolism. MGL-3196 reduces lipotoxicity associated with NASH, and in NASH preclinical models, MGL-3196 reduces hepatic triglycerides and markers of inflammation and fibrosis.
200 Barr Harbor Dr Ste 400
The company trades on NASDAQ exchange. The company headquarter is located in Massachusetts, MA. The company was established in the 2011.| Ticker | MDGL |
| Long Name | Madrigal Pharmaceuticals, Inc. |
| Short Name | Madrigal Pharma |